Substituent effect of <i>N</i>
-aryl-<i>N</i>
′-pyridyl ureas as thermal latent initiators on ring-opening polymerization of epoxide
作者:Naoyuki Makiuchi、Atsushi Sudo、Takeshi Endo
DOI:10.1002/pola.27726
日期:2015.11.15
series of N‐aryl‐N′‐pyridyl ureas were synthesized by the reactions of 4‐aminopyridine (4AP) with the corresponding isocyanates such as phenyl isocyanate, 4‐methylphenyl isocyanate, 4‐methoxyphenyl isocyanate, 4‐chlorophenyl isocyanate, 4‐(trifluoromethyl)phenyl isocyanate, and 4‐nitrophenyl isocyanate. Bulk polymerization of diglycidyl ether of bisphenol A (DGEBA) in the presence of the ureas as initiators
atom economy has been developed for the synthesis of N-aryl-N′-(4-pyridinyl)ureas. With cheap selenium as the catalyst, carbonmonoxide (instead of phosgene) as the carbonyl reagent, N-aryl-N′-(4-pyridinyl)ureas can be obtained in a one-pot manner mostly in moderate to good yields via oxidative cross-carbonylation of 4-aminopyridine with a variety of aromaticamines in the presence of oxygen under atmospheric
N-Phenyl-N'-pyridinylureas as anticonvulsant agents
作者:Michael R. Pavia、Sandra J. Lobbestael、Charles P. Taylor、Fred M. Hershenson、David L. Miskell
DOI:10.1021/jm00164a061
日期:1990.2
A series of N-phenyl-N'-pyridinylureas was examined for anticonvulsant activity. Extensive structure/activity investigations revealed optimal activity in the N-(2,6-disubstituted-phenyl)-N'-(4-pyridinyl)urea series, with 37 exhibiting the best overall anticonvulsant profile. Compound 37 was effective against seizures induced by maximal electroshock but did not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that 37 would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound 37 was selected for Phase 1 clinical trials.
Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
申请人:Tao Chunlin
公开号:US20120270858A1
公开(公告)日:2012-10-25
The invention provides isoquinoline, quinoline, and quinazoline derivatives to treat a variety of disorders, diseases and pathologic conditions, and more specifically to the use of isoquinoline, quinoline, and quinazoline derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds to the treatment of hyperproliferative diseases and pathologic angiogenesis.